Planview Reports Record Q2 and H1 2023, Continues Momentum Amid Challenging Economic Landscape
20.7.2023 18:18:00 EEST | Business Wire | Press release
Planview, the leading platform for digital connected work from portfolio planning to delivery, announced today record annual recurring revenue (ARR) and bookings in Q2, continuing strong momentum and growth in 2023. ACV Bookings for Q2 and the first half of the year were at a record high approaching 30% growth year-over-year (YoY), driven by both new customer additions and customer expansions across financial services, automotive, and healthcare. At the close of H1 2023, Planview is outpacing its forecasts on several key measures, including bookings, retention, and ARR this year. These results are driven by significant demand from customers who require data-driven insights to effectively prioritize initiatives, allocate capital and utilize resources across digital transformation efforts.
“The macroenvironment continues to pose challenges for digital transformation efforts in companies around the world. Organizations are faced with inflation, changing customer expectations, and more conservative budgets,” said Razat Gaurav, CEO at Planview. “At the same time, they must continue to drive forward transformation initiatives to adapt and achieve key business outcomes. Planview’s connected solution is uniquely positioned to give leaders and organizations the data-driven alignment, transparency, and visibility to make critical prioritization decisions, enabling companies to increase productivity, improve time-to-market, and de-risk strategic bets.”
H1 2023 Highlights
- Strong ACV bookings growth for the first half of 2023, approaching 30% growth YoY
- Significant improvements to Retention through first half of 2023, +100bps improvement to Net Retention YoY
- Recurring Revenue grew 13% during the first half of 2023 YoY
- Added over 126 net new customers
- Grew total active users for University of Planview by 29% quarter-over-quarter
Strong New Logo and Customer Momentum
Planview’s outperformance and profitable growth has been driven by new customer wins and expansions. New and notable customers who partnered or significantly expanded their footprint with Planview include AT&T, Axcelis Technologies, Bausch + Lomb, Baylor Scott & White Health, CellCarta, ChristianaCare, Commonwealth Bank of Australia, Corewell Health, Ecopetrol Group, Foodstuffs, Ford Motor Company, Inland Empire Health Plan, LandSure Systems, Mitsubishi UFJ Financial Group, New York Life Insurance Company, Omnicell, OneSavings Bank, PagoNxt, Pladis Global, Schaeffler Group, Schwab, Sherwin-Williams, Sun Life Financial, Transport for NSW, Tronox Holdings, Vanguard Group, Vonage, and Voya.
Industry Leadership & Product Innovation
Key milestones that support continued customer success and the company's strong growth:
- Showcased new Generative AI based assistant at the Reuters Momentum AI Summit.
- Released the landmark 2023 Project to Product State of the Industry Report, which revealed that 40% of Digital Innovation work is being wasted today.
- Recognized for the second consecutive year as a leader in the 2023 Gartner® Magic Quadrant™ for Strategic Portfolio Management. The company was positioned furthest for Completeness of Vision.
- Expanded its global footprint with growing teams in North America, EMEA, Israel and India, with a focus on Artificial Intelligence (AI), Data Science, R&D, Premium Support, Managed Services, InfoSec, and Partners/Strategic Alliances.
- Increased its global partner ecosystem with the additions of UiPath and NTT Data, focused on delivering Value Stream Management capabilities.
- Dramatically expanded its partnership with AWS, including achievement of AWS ISV Accelerate Program membership and the launch of five Planview solutions in the AWS Marketplace.
- Increased in monthly active users by 15% YoY for leading products.
Planview is continuing to invest heavily in product innovation, customer success and go-to-market, building a foundation for continued customer satisfaction and growth in 2023 and beyond.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720450990/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom